FDA approves first generic Suboxone

Jun 18, 2018

Mylan and Dr. Reddy's Laboratories have both received FDA approval to make the first generic versions of a Suboxone under-the-tongue film for the treatment of opioid addiction.

However, approval does not mean the generic product — a film strip that combines buprenorphine and naloxone — will quickly enter the market. Indivior, the patent-holder, announced that U.S. district court of New Jersey had granted it a restraining order compelling rival drugmaker Dr. Reddy's to temporarily cease activities related to the development and marketing of the drug. Mylan had previously reached a settlement with Indivior, agreeing to delay launching its generic until 2023.

The Suboxone brand brought in as much as $2 billion in sales a year for U.K.-based Indivior.

Read the FDA announcement 


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments